Sevoflurane increases glucose transport in skeletal muscle cells.
Sevoflurane activates phospholipase C and protein kinase C, leading to an increase in intracellular Ca(2+) concentration, which modulates glucose transport. We studied in vitro the effect of sevoflurane on the uptake of 2-deoxyglucose in rat skeletal muscle cells and the mechanism that modulates the glucose transport. Sevoflurane 0.8, 1.2, and 2.0 mM significantly increased glucose uptake from 13.1 +/- 1.2 pmol. h(-1). mg protein(-1) to 22.6 +/- 1.4, 32.1 +/- 1.8, and 37.4 +/-2.7 pmol. h(-1). mg protein(-1), respectively. Tyrphostin A-23 (a highly selective tyrosine kinase inhibitor) 1 and 10 nM significantly decreased the sevoflurane-stimulated glucose uptake from 32.1 +/- 1.8 to 25.8 +/- 1.1 and 15.2 +/- 1.7 pmol. h(-1). mg protein(-1), respectively. Genistein (a selective tyrosine kinase inhibitor) 1 and 10 nM also significantly decreased the sevoflurane- stimulated glucose uptake from 32.1 +/- 1.8 to 25.7 +/- 1.5 and 15.2 +/- 1.4 pmol. h(-1). mg protein(-1), respectively. The sevoflurane-stimulated glucose uptake was decreased by 100 nM and 1 microM TMB-8 (an intracellular Ca(2+) antagonist), from 32.1 +/- 1.8 pmol. h(-1). mg protein(-1) to 25.6 +/- 3.3 and 20.3 +/- 1.6 pmol. h(-1). mg protein(-1), respectively. Staurosporine (a protein kinase C antagonist) 100 nM significantly decreased sevoflurane-stimulated glucose uptake to 26.1 +/- 1.5 pmol. h(-1). mg protein(-1). We conclude that sevoflurane increases glucose uptake in skeletal muscle cells and that the sevoflurane-stimulated glucose uptake was associated with tyrosine kinase, protein kinase C, and intracellular Ca(2+).


CONCLUSIONS
Sevoflurane anesthesia has an inhibitory effect on insulin secretion. Glucose concentrations in plasma do not significantly change during sevoflurane anesthesia. Plasma glucose concentrations are affected by intracellular glucose metabolism. However, glucose transport into cells during sevoflurane anesthesia remains unclear.
Kudoh
Akira
A
Department of Anesthesiology, University of Hirosaki School of Medicine, Hirosaki National Hospital, 1 Tominocho, Hirosaki 036-8545, Aomori, Japan.
Katagai
Hiroshi
H
Takazawa
Tomoko
T
D018685:Anesthetics, Inhalation / Q000494:pharmacology*; D000818:Animals; D000963:Antimetabolites / Q000378:metabolism; D001693:Biological Transport, Active / Q000187:drug effects; D002118:Calcium / Q000378:metabolism; D002469:Cell Separation; D003847:Deoxyglucose / Q000378:metabolism; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005947:Glucose / Q000378:metabolism*; D066298:In Vitro Techniques; D008738:Methyl Ethers / Q000494:pharmacology*; D018482:Muscle, Skeletal / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D051381:Rats; D000077149:Sevoflurane
D018685:Anesthetics, Inhalation; D000963:Antimetabolites; D002118:Calcium; D003847:Deoxyglucose; D004791:Enzyme Inhibitors; D005947:Glucose; D008738:Methyl Ethers; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011493:Protein Kinase C; D011505:Protein-Tyrosine Kinases; D000077149:Sevoflurane